Ad-Funded Physician Adoption and Enterprise Expansion

The key advantage is that free distribution turns physician attention into both the growth engine and the product moat. OpenEvidence can spread one doctor at a time without waiting for a hospital contract, then use that daily usage to sell premium pharma advertising and later walk into health systems with proof that their clinicians already rely on it. That is a much faster path than starting with a top down hospital sale.

• The ad model works because the audience is unusually valuable. OpenEvidence has sold pharma and med device inventory at roughly $70 to $150+ CPM, with estimated annualized revenue rising from about $50M in June 2025 to $150M by late 2025. Doximity shows the same logic at scale, with $570.4M fiscal 2025 revenue and most revenue tied to marketing solutions.
  2 sacra 3 sacra 6 q4cdn
• Free access also removes the main friction in healthcare software adoption. Because the core product can be used without touching patient records, it can spread through word of mouth instead of an 18 month procurement cycle. That bottom up foothold is what makes later enterprise expansion plausible, especially through EHR embedding and SMART on FHIR style integrations.
  1 sacra 2 sacra 5 ucsf
• The comparison with UpToDate shows where monetization can expand. UpToDate built a large business through seat based licensing and is now packaging enterprise wide deployments with AI features. OpenEvidence can start with ads to win usage, then layer on enterprise workflow products once hospitals want the tool inside Epic or Cerner rather than in a separate browser tab.
  1 sacra 4 doximity 5 ucsf 7 wolterskluwer

The next phase is a hybrid model. Advertising should keep funding rapid physician acquisition, while workflow products, EHR integrations, and broader care team deployments raise revenue per account. If OpenEvidence keeps converting daily doctor usage into embedded hospital software, it can move from being a free research tool to a core clinical interface.